Luis F Lopez-Cortes

Summary

Country: Spain

Publications

  1. pmc Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients
    Luis F Lopez-Cortes
    Unidad Clínica de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocío Instituto de Biomedicina de Sevilla, Seville, Spain
    PLoS ONE 7:e28115. 2012
  2. ncbi request reprint Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis
    Luis F Lopez-Cortes
    Infectious Diseases Service, University Hospital Virgen del Rocio, Seville, Spain
    Clin Pharmacokinet 41:681-90. 2002
  3. ncbi request reprint Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations
    Luis F Lopez-Cortes
    Infectious Diseases Service, Hospitales Universitarios Virgen del Rocio, Seville, Spain
    J Acquir Immune Defic Syndr 39:551-6. 2005
  4. doi request reprint [Pharmacology, pharmacokinetic features and interactions of atazanavir]
    Luis F Lopez-Cortes
    Servicio de Enfermedades Infecciosas, Hospital Universitario Virgen del Rocio, Sevilla, Espana
    Enferm Infecc Microbiol Clin 26:2-8. 2008
  5. ncbi request reprint Influence of treatment and immunological recovery on tuberculosis relapses in HIV-infected patients
    L F Lopez-Cortes
    Department of Infectious Diseases Service, Hospitales Universitarios Virgen del Rocio, Seville, Spain
    Int J Tuberc Lung Dis 9:1385-90. 2005
  6. ncbi request reprint Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen
    Luis F Lopez-Cortes
    Infectious Diseases Service, Hospitales Universitarios, Virgen del Rocio, Seville, Spain
    J Antimicrob Chemother 58:1017-23. 2006
  7. ncbi request reprint Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy
    Luis F Lopez-Cortes
    Infectious Diseases Service, Hospitales Universitarios Virgen del Rocio, Seville, Spain
    Ther Drug Monit 29:171-6. 2007
  8. pmc Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study
    Luis F Lopez-Cortes
    Servicio de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocio, Instituto de Biomedicina de Sevilla, Seville, Spain
    AIDS Res Ther 7:5. 2010
  9. doi request reprint Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients
    L F Lopez-Cortes
    Instituto de Biomedicina de Sevilla, Servicio de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocio, Seville, Spain
    Clin Pharmacol Ther 84:573-80. 2008
  10. ncbi request reprint Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients
    Jose A Mira
    Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    Antivir Ther 12:1225-35. 2007

Collaborators

Detail Information

Publications34

  1. pmc Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients
    Luis F Lopez-Cortes
    Unidad Clínica de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocío Instituto de Biomedicina de Sevilla, Seville, Spain
    PLoS ONE 7:e28115. 2012
    ..We evaluated the efficacy of a lower peginterferon-α 2a dose and a shorter duration of therapy than the current standard of care in genotype 3 HCV/HIV-coinfected patients...
  2. ncbi request reprint Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis
    Luis F Lopez-Cortes
    Infectious Diseases Service, University Hospital Virgen del Rocio, Seville, Spain
    Clin Pharmacokinet 41:681-90. 2002
    ..To evaluate the pharmacokinetic interactions between efavirenz and rifampicin (rifampin) in patients with HIV infection and tuberculosis...
  3. ncbi request reprint Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations
    Luis F Lopez-Cortes
    Infectious Diseases Service, Hospitales Universitarios Virgen del Rocio, Seville, Spain
    J Acquir Immune Defic Syndr 39:551-6. 2005
    ..We explore whether a limited sampling strategy could provide a good estimation of EFV trough levels and area under the curve (AUC)...
  4. doi request reprint [Pharmacology, pharmacokinetic features and interactions of atazanavir]
    Luis F Lopez-Cortes
    Servicio de Enfermedades Infecciosas, Hospital Universitario Virgen del Rocio, Sevilla, Espana
    Enferm Infecc Microbiol Clin 26:2-8. 2008
    ....
  5. ncbi request reprint Influence of treatment and immunological recovery on tuberculosis relapses in HIV-infected patients
    L F Lopez-Cortes
    Department of Infectious Diseases Service, Hospitales Universitarios Virgen del Rocio, Seville, Spain
    Int J Tuberc Lung Dis 9:1385-90. 2005
    ..Studies on tuberculosis (TB) relapse in HIV-infected patients show contradictory results regarding the optimal duration of treatment...
  6. ncbi request reprint Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen
    Luis F Lopez-Cortes
    Infectious Diseases Service, Hospitales Universitarios, Virgen del Rocio, Seville, Spain
    J Antimicrob Chemother 58:1017-23. 2006
    ....
  7. ncbi request reprint Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy
    Luis F Lopez-Cortes
    Infectious Diseases Service, Hospitales Universitarios Virgen del Rocio, Seville, Spain
    Ther Drug Monit 29:171-6. 2007
    ..Nevertheless, therapeutic drug monitoring is advisable to maintain appropriate levels throughout pregnancy...
  8. pmc Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study
    Luis F Lopez-Cortes
    Servicio de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocio, Instituto de Biomedicina de Sevilla, Seville, Spain
    AIDS Res Ther 7:5. 2010
    ..SQV 500 mg strength tablets became available at the end of 2005, thus facilitating a once-daily regimen with fewer pills, although there is very limited experience with this formulation yet...
  9. doi request reprint Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients
    L F Lopez-Cortes
    Instituto de Biomedicina de Sevilla, Servicio de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocio, Seville, Spain
    Clin Pharmacol Ther 84:573-80. 2008
    ..Early therapeutic drug monitoring of pegIFN-alpha-2a levels could be beneficial in improving current treatment outcomes...
  10. ncbi request reprint Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients
    Jose A Mira
    Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    Antivir Ther 12:1225-35. 2007
    ..The objective of this study was to identify predictors of severe haematological toxicity among HIV-HCV-coinfected patients treated with PEG-IFN plus RBV...
  11. ncbi request reprint Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients
    Juan A Pineda
    Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Sevilla, Spain
    J Antimicrob Chemother 60:1347-54. 2007
    ....
  12. doi request reprint Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients
    José del Valle
    Infectious Diseases Unit, Hospital Universitario de Valme, Sevilla, Spain
    AIDS 22:923-30. 2008
    ..There are no data concerning this topic in HIV/hepatitis C virus coinfected patients in whom lipid disorders are particularly common...
  13. ncbi request reprint Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients
    Jose A Mira
    Hospital Universitario de Valme, Sevilla, Spain
    Antivir Ther 12:523-9. 2007
    ..Our objective was to determine if rapid virological response (RVR) at week 4 of therapy with peg-IFN and RBV could predict SVR among HIV/HCV-coinfected patients...
  14. doi request reprint Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients
    Juan Macias
    Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, Seville, Spain
    Hepatology 56:1261-70. 2012
    ..Cumulative exposure to dideoxynucleoside analogs and increases in FPG are related with HS progression. Stetatohepatitis is frequently observed in these patients and is linked to fibrosis progression...
  15. doi request reprint Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load
    Karin Neukam
    Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain
    J Hepatol 56:788-94. 2012
    ....
  16. doi request reprint Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus
    Juan Macias
    Infectious Diseases Unit, Hospital Universitario de Valme, Seville, Spain
    Hepatology 50:1056-63. 2009
    ..61 [0.39-0.93], P = 0.03), moderate-to-severe lobular necroinflammation (1.77 [1.16-2.7], P = 0.009), time between biopsies (1.11 [1.08-1.2], P = 0.01), and end of treatment response to anti-HCV therapy (0.41 [0.19-0.88], P = 0.02)...
  17. ncbi request reprint Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C
    Juan Macias
    Hospital Universitario de Valme, Seville, Spain
    Antivir Ther 11:839-46. 2006
    ..The use of PI-based HAART in HIV/HCV-coinfected patients is associated with less severe fibrosis and slower progression of fibrosis. The nucleoside analogue backbone in a HAART regimen may influence this association...
  18. doi request reprint Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone
    Jose A Mira
    Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Sevilla, Spain
    J Antimicrob Chemother 62:1365-73. 2008
    ....
  19. ncbi request reprint Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients
    Jose A Mira
    Unidad de Enfermedades Infecciosas y Microbiología Clinica, Hospital Universitario de Valme, Seville, Spain
    AIDS 26:1721-4. 2012
    ..The efficacy of peg-IFN with RBV in coinfected individuals with genotype 4 is significantly higher than in those with genotype 1. IL28B CC genotype is the main predictor of response in this population...
  20. doi request reprint Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients
    Juan Macias
    aInfectious Diseases and Microbiology Unit, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla, Seville bInfectious Diseases Unit, Instituto Maimonides de Investigacion Biomedica de Cordoba, Hospital Universitario Reina Sofia, Cordoba cInfectious Diseases Unit, Hospital Donostia, San Sebastian dInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío CSIC Universidad de Sevilla, Seville eInfectious Diseases Unit, Hospital General Universitario de Valencia, Valencia fInternal Medicine Service, FundacióLluita Contra la SIDA, University Hospital GermansTrias I Pujol, Universitatautonoma de Barcelona, Barcelona gInfectious Diseases Unit, Hospital Universitario Virgen Macarena, Seville hInfectious Diseases Unit, Complejo Hospitalario de Huelva, Huelva iInfectious Diseases Unit, Hospital de la Línea de la Concepción, Cadiz jInfectious Diseases Unit, Hospital Universitario Virgen de la Victoria, Malaga, Spain
    AIDS 27:2541-9. 2013
    ..To compare the prognostic performance of liver biopsy with that of liver stiffness measurement (LSM) to predict survival and liver decompensations among HIV/hepatitis C virus (HCV)-coinfected patients...
  21. doi request reprint Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients
    Nicolas Merchante
    Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Sevilla, Spain
    AIDS Patient Care STDS 25:395-402. 2011
    ..Thus, ART regimens containing FPV/r QD may be considered safe in HIV/HCV-coinfected patients, including those with cirrhosis...
  22. ncbi request reprint Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial
    Alicia Gutiérrez-Valencia
    Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocio, Universidad de Sevilla, and Hospital Universitario de Valme, Seville, Spain
    Ann Intern Med 151:149-56. 2009
    ..More than 50% of patients who start efavirenz treatment develop limiting neuropsychiatric adverse events (NPAEs)...
  23. pmc Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients
    Luis F Lopez-Cortes
    Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío CSIC Universidad de Sevilla, Seville, Spain
    Antimicrob Agents Chemother 57:3746-51. 2013
    ..Tight control of viral replication in the previous months and strict adherence throughout the mtLPVr regimen could improve the virological efficacy of this maintenance regimen...
  24. pmc Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000-2010
    Beatriz De Felipe
    Laboratory of Immunovirology, Infectious Diseases Service, Instituto Ramón y Cajal de Investigaciones Cientificas IRYCIS, Hospital Universitario Ramon y Cajal, Madrid, Spain
    Virol J 8:416. 2011
    ..The objective of this study was to evaluate the prevalence of non-B subtypes circulating in a cohort of HIV-1-infected immigrants in Seville, Southern Spain and to identify drug resistance-associated mutations...
  25. doi request reprint Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients
    Juan Macias
    Clinical Unit of Infectious Diseases, Department of Internal Medicine, Seville, Spain
    J Hepatol 49:916-22. 2008
    ..Because of this, we elaborated and validated cut-off values of liver stiffness (LS) to better discriminate F < or = 1 from F > or = 2 in HIV/HCV co-infected subjects to aid therapy decisions...
  26. pmc Molecular epidemiology of HIV type 1 in newly diagnosed patients in southern Spain
    Michael J McConnell
    Servicio de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocio, Seville, Spain
    AIDS Res Hum Retroviruses 24:881-7. 2008
    ..These results elucidate the subtype diversity present in this region and suggest that the transmission of highly resistant virus variants does not occur at a high frequency in this population...
  27. ncbi request reprint Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequences
    Rosario C Mata
    Servicio de Enfermedades Infecciosas, Hospital Universitario Virgen del Rocio, Sevilla, Spain
    AIDS Patient Care STDS 19:550-62. 2005
    ..Furthermore, there is a considerable concern about the development of drug resistance and the possibility of an incomplete immune reconstitution after the treatment interruption in some patients...
  28. doi request reprint Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy
    Almudena Torres-Cornejo
    Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen del Rocío Instituto de Biomedicina de Sevilla IBiS, Hospital Universitario Virgen del Rocío CSIC Universidad de Sevilla, Av Manuel Siurot, Sevilla, Spain
    AIDS 28:201-8. 2014
    ..To assess the impact of blips and persistent viremia episodes on cell-associated HIV-DNA reservoir in extensively pretreated patients receiving ritonavir-boosted darunavir monotherapy (MtDRV/rtv) for 24 months...
  29. doi request reprint Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients
    Juan A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Hospital Universitario Virgen del Rocio, Seville, Spain
    Clin Infect Dis 49:1274-82. 2009
    ..To provide information about the incidence and predictors of liver decompensation and death due to liver failure in human immunodeficiency virus (HIV)-infected patients with compensated hepatitis C virus (HCV)-related cirrhosis...
  30. doi request reprint Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients
    Juan Macias
    Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain
    HIV Clin Trials 13:61-9. 2012
    ....
  31. doi request reprint Virological and immunological stability in HIV infected patients undergoing partial-treatment interruption
    Rosario C Mata
    Servicio de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocio, Instituto de Biomedicina de Sevilla IBiS, Sevilla, Spain
    J Clin Virol 45:362-6. 2009
    ....
  32. pmc Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population
    Luis F Lopez-Cortes
    Instituto de Biomedicina de Sevilla IBiS, Hospital Universitario Virgen del Rocío CSIC Universidad de Sevilla, Sevilla, Spain Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen del Rocio, Sevilla, Spain
    PLoS ONE 9:e97262. 2014
    ..2% of the subjects. In conclusion, ETV (once- or twice daily) plus two analogs is a suitable, well-tolerated combination both as a switching strategy and after failure with first generation NNRTIs, ensuring full drug activity...
  33. doi request reprint Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients
    Alicia Gutiérrez-Valencia
    Unidad Clínica de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocío Instituto de Biomedicina de Sevilla, Seville, Spain
    J Antimicrob Chemother 67:681-4. 2012
    ..To compare intracellular and plasma etravirine concentrations when etravirine was given at 200 mg/12 h versus 400 mg/24 h and to evaluate whether the results would support once-daily dosing...
  34. doi request reprint Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine
    Maria Del Mar Del Pozo Balado
    Immunovirology Laboratory, Infectious Diseases Service, Clinical Biochemistry Service, Institute of Biomedicine of Seville IBIS, Virgen del Rocio University Hospital, Seville, Spain
    J Infect Dis 202:362-9. 2010
    ..These findings suggest an active role played by T(reg) cells on the immunization antigen-specific T and/or B cell responses with the final consequence of a B cell anti-HBs lower production...